Drug Delivery and Therapeutic Impact of extended-release Acetylsalicylic Acid

Bliden, Kevin P.; Patrick, Jeff; Pennell, Andrew T; Tantry, Udaya S.; Gurbel, Paul A.

doi:10.2217/fca.15.60

Cited by 16 publications

(6 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When treated on MSCs, ASA is capable of elevating BMMSCs-mediated bone regeneration (Liu et al, 2011) and improving stem cells from human exfoliated deciduous teeth (SHED) osteogenic differentiation capacity (Liu et al, 2015). However, as ASA possessed a rapid dissolution profile and short half-life in vivo (Bliden et al, 2016), fabricating a suitable scaffold and delivery system to carry and sustain ASA efficacy at the site of bone repair is essential.…”

Section: Introductionmentioning

confidence: 99%

A Tetra-PEG Hydrogel Based Aspirin Sustained Release System Exerts Beneficial Effects on Periodontal Ligament Stem Cells Mediated Bone Regeneration

et al. 2019

View full text Add to dashboard Cite

Bone defects, massive bone defects in particular, is still an issue clinically. Acetylsalicylic acid (ASA), also known as aspirin, has been proven to be conducive for mesenchymal stem cells osteogenic differentiation, which may be benefited for bone regeneration. In order to achieve a more appealing prognosis of bone defect, here we develop a well-defined tetra-PEG hydrogel sealant with rapid gelation speed, strong tissue adhesion, and high mechanical strength. After in-situ encapsulation of aspirin, this drug-loaded tetra-PEG hydrogel possessed a sustained release, anti-inflammation, and osteoinductive properties. In vitro experiments showed that the cell proliferation was slightly facilitated, and the osteogenic differentiation was notably augmented when periodontal ligament stem cells (PDLSCs) were co-incubating with the hydrogel materials. Moreover, in vivo study manifested that the aspirin sustained release system significantly facilitated the PDLSCs mediated bone defect regeneration. Overall, tetra-PEG hydrogel-based aspirin sustained release system is applicable not only for enhancing the osteogenesis capacity of PDLSC but also providing a new thought of bone regenerative therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

A Tetra-PEG Hydrogel Based Aspirin Sustained Release System Exerts Beneficial Effects on Periodontal Ligament Stem Cells Mediated Bone Regeneration

et al. 2019

View full text Add to dashboard Cite

show abstract

“…To address the unmet medical need for 24-h antiplatelet coverage in high-risk populations, an extended-release aspirin (Durlaza®, New Haven Pharmaceuticals, Inc., North Haven, CT) was developed and approved in the United States in 2015. 9 In addition, ongoing studies are now investigating the utility of deleting aspirin therapy in the setting of potent P2Y 12 receptor blockade with ticagrelor or replacing it with a new oral anticoagulant.…”

Section: Aspirinmentioning

confidence: 99%

“…However, the clinical importance of this pharmacodynamic interaction remains highly controversial. 9 These investigations failed to demonstrate the utility of platelet function testing in reducing the post-PCI ischemic risk. Major criticism for the latter neutral observation are: all these investigations used the VerifyNow P2Y12 assay to assess platelet reactivity to ADP and to identify HPR, these investigations included mostly low-risk patients undergoing PCI and had resultant low event rates irrespective of platelet reactivity.…”

Section: Clopidogrelmentioning

confidence: 99%

State of the art: Oral antiplatelet therapy

Gurbel

Myat

Kubica

et al. 2016

JRSM Cardiovascular Disease

Self Cite

View full text Add to dashboard Cite

Platelet adhesion, activation, and aggregation are central to the propagation of coronary thrombosis following rupture, fissure, or erosion of an atherosclerotic plaque. This chain of deleterious events underlies the pathophysiological process leading to an acute coronary syndrome. Therefore, oral antiplatelet therapy has become the cornerstone of therapy for the management of acute coronary syndrome and the prevention of ischemic complications associated with percutaneous coronary intervention. Landmark trials have established aspirin, and the addition of clopidogrel to aspirin, as key therapeutic agents in the context of acute coronary syndrome and percutaneous coronary intervention. Dual antiplatelet therapy has been the guideline-mandated standard of care in acute coronary syndrome and percutaneous coronary intervention. Despite the proven efficacy of dual antiplatelet therapy, adverse ischemic events continue to occur and this has stimulated the development of novel, more potent antiplatelet agents. We focus this state-of-the-art review on the most recent advances in oral antiplatelet therapy, treading the tightrope of potency versus bleeding risk, the quest to determine the optimal duration of dual antiplatelet therapy and future of personalized antiplatelet therapy.

show abstract

“…Acetylsalicylic acid (ASA) is a widely used nonsteroidal anti-inflammatory drug that can affect multiple biological processes and the local microenvironment of mesenchymal stem cells in MSC-mediated bone regeneration. It can elevate the osteogenic differentiation through activation of osteoblasts and inhibition of osteoclasts ( Yamaza et al, 2008 ), but its rapid dissolution nature and short half-life greatly limit its clinical applications ( Bliden et al, 2016 ), which urgently require a suitable scaffold and drug delivery system to achieve sustainable transportation at the site of bone repair. A recent study reported an aspirin-based tetra-PEG hydrogel with a sustained release system to promote the osteogenesis performance, but simultaneously satisfying mechanics and cell proliferation is necessarily improved in bone regeneration ( Yunfan Zhang et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Fabrication of Naturally Derived Double-Network Hydrogels With a Sustained Aspirin Release System for Facilitating Bone Regeneration

Zhu¹,

Chen²,

Wang³

et al. 2022

Front. Chem.

View full text Add to dashboard Cite

Continuous efforts on pursuit of effective drug delivery systems for engineering hydrogel scaffolds is considered a promising strategy for the bone-related diseases. Here, we developed a kind of acetylsalicylic acid (aspirin, ASA)–based double-network (DN) hydrogel containing the positively charged natural chitosan (CS) and methacrylated gelatin (GelMA) polymers. Combination of physical chain-entanglement, electrostatic interactions, and a chemically cross-linked methacrylated gelatin (GelMA) network led to the formation of a DN hydrogel, which had a suitable porous structure and favorable mechanical properties. After in situ encapsulation of aspirin agents, the resulting hydrogels were investigated as culturing matrices for adipose tissue–derived stromal cells (ADSCs) to evaluate their excellent biocompatibility and biological capacities on modulation of cell proliferation and differentiation. We further found that the long-term sustained ASA in the DN hydrogels could contribute to the anti-inflammation and osteoinductive properties, demonstrating a new strategy for bone tissue regeneration.

show abstract

Drug Delivery and Therapeutic Impact of extended-release Acetylsalicylic Acid

Cited by 16 publications

References 75 publications

A Tetra-PEG Hydrogel Based Aspirin Sustained Release System Exerts Beneficial Effects on Periodontal Ligament Stem Cells Mediated Bone Regeneration

A Tetra-PEG Hydrogel Based Aspirin Sustained Release System Exerts Beneficial Effects on Periodontal Ligament Stem Cells Mediated Bone Regeneration

State of the art: Oral antiplatelet therapy

Fabrication of Naturally Derived Double-Network Hydrogels With a Sustained Aspirin Release System for Facilitating Bone Regeneration

Contact Info

Product

Resources

About